Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

The purpose of this study is to find out if there is a benefit to giving rituximab with etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R-EPOCH) in participants who have high-risk B-cell PTLD in their 2nd phase of treatment (consolidation) while those with low-risk disease will be spared of chemotherapy and treated with rituximab consolidation alone. This study is also being done to find out about the usefulness of circulating tumor DNA (ctDNA), a novel blood test which, has been shown to help guide treatment decisions in other types of lymphoma. The goal is to answer th

Trial Details

NCT ID
NCT06954805
Phase
PHASE2
Sponsor
Jennifer Amengual
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Rituximab
  • Etoposide
  • Prednisone
  • Vincristine
  • Cyclophosphamide
  • Doxorubicin
Locations (sample)
  • Stanford, California, United States|37.42411,-122.16608
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Histologically confirmed CD20+ PTLD including the below subtypes:
  • Polymorphic
  • Monomorphic
  • Participants must have measurable disease, defined as lymph node ≥ 1.5 cm in greatest diameter per Lugano Classification

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →